FDA grants clearance for Endogena’s age-related macular degeneration treatment
The company will launch a clinical investigation of EA-2351 for geographic atrophy
Read More
Tag: EA-2351
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
